ABP 501 与阿达木单抗治疗中重度斑块状银屑病的临床相似性Ⅲ期研究
这项 52 周双盲多中心Ⅲ期研究将中重度银屑病患者随机分配至 ABP 501 或阿达木单抗。第 16 周时,ABP 501 组 PASI 改善 80.9,阿达木单抗组为 83.1,最小二乘均值差 -2.18(95%CI -7.39 至 3.02),落在 ±15 的等效界内,达到临床相似性的主要终点。安全性及免疫原性在单次转换后也相似。
要点
- ABP 501 与阿达木单抗第 16 周 PASI 改善的差值 95%CI 在 ±15 等效界内。
- 不良事件发生率 ABP 501 组 67.2%、阿达木单抗组 63.6%,两组相似。
- 第 16 周单次由阿达木单抗转换为 ABP 501 后,安全性与免疫原性未立即受影响。
核心结论
- ABP 501 在治疗中重度斑块状银屑病方面与阿达木单抗具有临床相似性。
- 单次由阿达木单抗转换为 ABP 501 后,安全性和免疫原性未立即受到影响。
研究设计与样本
- 52 周、双盲、多中心、随机Ⅲ期研究,纳入中重度斑块状银屑病患者。
- 第 16 周时,ABP 501 组中 PASI 改善≥50% 者继续原治疗,阿达木单抗组患者被再次随机分配至阿达木单抗或 ABP 501。
- 主要终点为基线至第 16 周 PASI 改善百分比的组间治疗差异,其点估计值及双侧 95%CI 需落在 ±15 等效界内。
主要发现
- 第 16 周 PASI 改善百分比:ABP 501 组 80.9,阿达木单抗组 83.1,最小二乘均值差 -2.18(95%CI -7.39 至 3.02)。
- 不良事件发生率:ABP 501 组 67.2%(117/174),阿达木单抗组 63.6%(110/173)。
- 抗药抗体发生率:ABP 501 组 55.2%(96/174),阿达木单抗组 63.6%(110/173)。
- 第 20 周(单次转换后)各组间安全性(包括免疫原性)相似。
关键数值与推荐
- 临床相似性判定标准:组间治疗差异点估计值及双侧 95%CI 在 ±15 等效界内。
- 第 16 周 PASI 改善百分比最小二乘均值差 -2.18(95%CI -7.39 至 3.02),符合上述等效界。
临床怎么用
- 对于适合阿达木单抗的中重度斑块状银屑病患者,ABP 501 可作为临床相似的生物类似药选择。
- 由阿达木单抗单次转换为 ABP 501 后短期内无需额外安全性担忧(基于第 20 周数据)。
局限性
- 本文未报告 52 周数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ABP 501 is a biosimilar of adalimumab. OBJECTIVE: We sought to compare the efficacy and safety of ABP 501 with adalimumab. METHODS: This 52-week, double-blind study randomized patients with moderate to severe psoriasis to ABP 501 or adalimumab. At week 16, those with 50% or more improvement in Psoriasis Area and Severity Index score from baseline on ABP 501 continued the same treatment, whereas adalimumab-treated patients were rerandomized to adalimumab or ABP 501. Clinical similarity in Psoriasis Area and Severity Index percent improvement from baseline to week 16 (primary end point) was established if the point estimate of treatment difference and its 2-sided 95% confidence interval between groups was within equivalence margin of ±15. Patients, including those undergoing a single transition at week 16, were evaluated for safety and immunogenicity. RESULTS: Psoriasis Area and Severity Index percent improvement at week 16 was 80.9 for ABP 501 and 83.1 for adalimumab (least-square mean difference -2.18 [95% confidence interval -7.39 to 3.02]). Adverse events (67.2% [117/174] vs 63.6% [110/173]) and antidrug antibody incidence (55.2% [96/174] vs 63.6% [110/173]) for ABP 501 vs adalimumab were similar. Safety, including immunogenicity, was similar among groups after single transition (week 20). LIMITATIONS: The 52-week data are not reported here. CONCLUSIONS: ABP 501 was shown to be clinically similar to adalimumab. Safety and immunogenicity were not impacted immediately after single transition (adalimumab to ABP 501).
引用
- Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017. PMID: 28291552. doi:10.1016/j.jaad.2016.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。